These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 20675134)
1. Discovery of imidazo[1,2-b]pyridazine derivatives as IKKbeta inhibitors. Part 1: Hit-to-lead study and structure-activity relationship. Shimizu H; Tanaka S; Toki T; Yasumatsu I; Akimoto T; Morishita K; Yamasaki T; Yasukochi T; Iimura S Bioorg Med Chem Lett; 2010 Sep; 20(17):5113-8. PubMed ID: 20675134 [TBL] [Abstract][Full Text] [Related]
2. Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 2: improvement of potency in vitro and in vivo. Shimizu H; Yasumatsu I; Hamada T; Yoneda Y; Yamasaki T; Tanaka S; Toki T; Yokoyama M; Morishita K; Iimura S Bioorg Med Chem Lett; 2011 Feb; 21(3):904-8. PubMed ID: 21232950 [TBL] [Abstract][Full Text] [Related]
3. Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: exploration of effective compounds in arthritis models. Shimizu H; Yamasaki T; Yoneda Y; Muro F; Hamada T; Yasukochi T; Tanaka S; Toki T; Yokoyama M; Morishita K; Iimura S Bioorg Med Chem Lett; 2011 Aug; 21(15):4550-5. PubMed ID: 21705219 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and evaluation of imidazo[1,2-b]pyridazine derivatives having a benzamide unit as novel VEGFR2 kinase inhibitors. Miyamoto N; Oguro Y; Takagi T; Iwata H; Miki H; Hori A; Imamura S Bioorg Med Chem; 2012 Dec; 20(24):7051-8. PubMed ID: 23123015 [TBL] [Abstract][Full Text] [Related]
5. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity. Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617 [TBL] [Abstract][Full Text] [Related]
7. IKKbeta inhibitors identification part I: homology model assisted structure based virtual screening. Nagarajan S; Doddareddy Mr; Choo H; Cho YS; Oh KS; Lee BH; Pae AN Bioorg Med Chem; 2009 Apr; 17(7):2759-66. PubMed ID: 19285872 [TBL] [Abstract][Full Text] [Related]
8. Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors. Byth KF; Cooper N; Culshaw JD; Heaton DW; Oakes SE; Minshull CA; Norman RA; Pauptit RA; Tucker JA; Breed J; Pannifer A; Rowsell S; Stanway JJ; Valentine AL; Thomas AP Bioorg Med Chem Lett; 2004 May; 14(9):2249-52. PubMed ID: 15081018 [TBL] [Abstract][Full Text] [Related]
9. Discovery of potent and selective rhodanine type IKKβ inhibitors by hit-to-lead strategy. Song H; Lee YS; Roh EJ; Seo JH; Oh KS; Lee BH; Han H; Shin KJ Bioorg Med Chem Lett; 2012 Sep; 22(17):5668-74. PubMed ID: 22858099 [TBL] [Abstract][Full Text] [Related]
10. The discovery of thienopyridine analogues as potent IkappaB kinase beta inhibitors. Part II. Wu JP; Fleck R; Brickwood J; Capolino A; Catron K; Chen Z; Cywin C; Emeigh J; Foerst M; Ginn J; Hrapchak M; Hickey E; Hao MH; Kashem M; Li J; Liu W; Morwick T; Nelson R; Marshall D; Martin L; Nemoto P; Potocki I; Liuzzi M; Peet GW; Scouten E; Stefany D; Turner M; Weldon S; Zimmitti C; Spero D; Kelly TA Bioorg Med Chem Lett; 2009 Oct; 19(19):5547-51. PubMed ID: 19716697 [TBL] [Abstract][Full Text] [Related]
11. Imidazo[1,2-b]pyridazines, novel nucleus with potent and broad spectrum activity against human picornaviruses: design, synthesis, and biological evaluation. Hamdouchi C; Sanchez-Martinez C; Gruber J; Del Prado M; Lopez J; Rubio A; Heinz BA J Med Chem; 2003 Sep; 46(20):4333-41. PubMed ID: 13678411 [TBL] [Abstract][Full Text] [Related]
12. Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. Morwick T; Berry A; Brickwood J; Cardozo M; Catron K; DeTuri M; Emeigh J; Homon C; Hrapchak M; Jacober S; Jakes S; Kaplita P; Kelly TA; Ksiazek J; Liuzzi M; Magolda R; Mao C; Marshall D; McNeil D; Prokopowicz A; Sarko C; Scouten E; Sledziona C; Sun S; Watrous J; Wu JP; Cywin CL J Med Chem; 2006 May; 49(10):2898-908. PubMed ID: 16686533 [TBL] [Abstract][Full Text] [Related]
13. Combination of pharmacophore model development and binding mode analyses: identification of ligand features essential for IκB kinase-beta (IKKβ) inhibitors and virtual screening based on it. Sun HP; Zhu J; Chen FH; Zhang SL; Zhang Y; You QD Eur J Med Chem; 2011 Sep; 46(9):3942-52. PubMed ID: 21708416 [TBL] [Abstract][Full Text] [Related]
14. Discovery of 6-aryl-7-alkoxyisoquinoline inhibitors of IkappaB kinase-beta (IKK-beta). Christopher JA; Bamborough P; Alder C; Campbell A; Cutler GJ; Down K; Hamadi AM; Jolly AM; Kerns JK; Lucas FS; Mellor GW; Miller DD; Morse MA; Pancholi KD; Rumsey W; Solanke YE; Williamson R J Med Chem; 2009 May; 52(9):3098-102. PubMed ID: 19348415 [TBL] [Abstract][Full Text] [Related]
15. Research on heterocyclic compounds. XXXIII--Synthesis and analgesic activity of imidazo[1,2-b]pyridazine-2-acetic acid derivatives. Luraschi E; Arena F; Sacchi A; Laneri S; Abignente E; D'Amico M; Berrino L; Rossi F Farmaco; 1995 May; 50(5):349-54. PubMed ID: 7626170 [TBL] [Abstract][Full Text] [Related]
16. A novel series of IKKβ inhibitors part I: Initial SAR studies of a HTS hit. Cushing TD; Baichwal V; Berry K; Billedeau R; Bordunov V; Broka C; Cardozo M; Cheng P; Clark D; Dalrymple S; DeGraffenreid M; Gill A; Hao X; Hawley RC; He X; Jaen JC; Labadie SS; Labelle M; Lehel C; Lu PP; McIntosh J; Miao S; Parast C; Shin Y; Sjogren EB; Smith ML; Talamas FX; Tonn G; Walker KM; Walker NP; Wesche H; Whitehead C; Wright M; Browner MF Bioorg Med Chem Lett; 2011 Jan; 21(1):417-22. PubMed ID: 21074993 [TBL] [Abstract][Full Text] [Related]
17. Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor. Bendjeddou LZ; Loaëc N; Villiers B; Prina E; Späth GF; Galons H; Meijer L; Oumata N Eur J Med Chem; 2017 Jan; 125():696-709. PubMed ID: 27721154 [TBL] [Abstract][Full Text] [Related]
18. Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors. Kaieda A; Takahashi M; Takai T; Goto M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Hamada T; Shirasaki M; Okada K; Snell G; Bragstad K; Sang BC; Uchikawa O; Miwatashi S Bioorg Med Chem; 2018 Feb; 26(3):647-660. PubMed ID: 29291937 [TBL] [Abstract][Full Text] [Related]
19. Imidazo[4,5-d]thiazolo[5,4-b]pyridine based inhibitors of IKK2: synthesis, SAR, PK/PD and activity in a preclinical model of rheumatoid arthritis. Dyckman AJ; Langevine CM; Quesnelle C; Kempson J; Guo J; Gill P; Spergel SH; Watterson SH; Li T; Nirschl DS; Gillooly KM; Pattoli MA; McIntyre KW; Chen L; McKinnon M; Dodd JH; Barrish JC; Burke JR; Pitts WJ Bioorg Med Chem Lett; 2011 Jan; 21(1):383-6. PubMed ID: 21087862 [TBL] [Abstract][Full Text] [Related]
20. Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IkappaB kinase. Kempson J; Guo J; Das J; Moquin RV; Spergel SH; Watterson SH; Langevine CM; Dyckman AJ; Pattoli M; Burke JR; Yang X; Gillooly KM; McIntyre KW; Chen L; Dodd JH; McKinnon M; Barrish JC; Pitts WJ Bioorg Med Chem Lett; 2009 May; 19(10):2646-9. PubMed ID: 19376699 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]